JeniVision is an early clinical stage biopharmaceutical company that strives to discover & develop innovative therapies in ophthalmology. Our proprietary non-invasive ocular delivery pathway (NIODP) enables successful drug delivery to the retina with high bioavailability. We have candidates in preclinical and clinical stages to not only treat debilitating diseases such as glaucoma and dry eye, but also prevent most common vision loss diseases like ROP, myopia and AMD. We believe that our innovative, non-invasive treatment for dry AMD will not only improve patient’s vision, but also prevent these patients from developing blinding wet AMD disease. With our creativity and ingenuity, we hope to forge new pathways in medicine for the future.
09/18/2023: JeniVision is pleased to announce the publication of our discovery of an innovative ocular delivery platform (NIODP). The manuscript entitled "Discovery and Potential Utility of a Novel Non-Invasive Ocular Delivery Platform", is published as an invited contribution for a special topic on "New Challenges in Ocular Drug Delivery" in Pharmaceutics (IF 6.525, 2022-2023). Please click the link or scan the QR code above for further reading.
June of 2022, JeniVision Receives Rare Pediatric Disease Designation from U.S. FDA for JV-MD2 (Omega-3 DHA) in Prevention of Retinopathy of Prematurity (ROP). JeniVision has been granted the Rare Pediatric Disease Designation by the U.S. Food and Drug Administration for JV-MD2 (omega-3 DHA), delivered by their proprietary Non-Invasive Ocular Delivery Platform (NIODP). This designation signifies the FDA's recognition of JV-MD2's potential in preventing Retinopathy of Prematurity (ROP), a serious eye condition affecting premature infants.
